In Vitro Activity of Daptomycin against Vancomycin-Resistant Enterococci of Various Van Types and Comparison of Susceptibility Testing Methods

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 12, 2003, Pages 3760-3763

  Jorgensen, James H ^a   Crawford, Sharon A ^a   Kelly, Cynthia C ^a   Patterson, Jan E ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; LINEZOLID; VANCOMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENETICS; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG ACTIVITY; ENTEROCOCCUS; ENTEROCOCCUS AVIUM; ENTEROCOCCUS CASSELIFLAVUS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; GENETIC SELECTION; IN VITRO STUDY; INTERMETHOD COMPARISON; NONHUMAN; PHYLOGENETIC TREE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULSED FIELD GEL ELECTROPHORESIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; CALCIUM; CARBON-OXYGEN LIGASES; CULTURE MEDIA; DAPTOMYCIN; DIFFUSION; ELECTROPHORESIS, GEL, PULSED-FIELD; ENTEROCOCCUS; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIAL SENSITIVITY TESTS; QUALITY CONTROL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; VANCOMYCIN RESISTANCE;

EID: 0344012042     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.12.3760-3763.2003     Document Type: Article

References (24)

1. Akins, R. L., and M. J. Rybak. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob. Agents Chemother. 45:454-459.
2. Alborn, W. E., Jr., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
3. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of daptomycin against 2,789 clinical isolates from 11 North American medical centers. Antimicrob. Agents Chemother. 45:1919-1922.
4. Bingen, E., C. Doit, N. Lambert-Zechovsky, et al. 1991. Bactericidal activity of daptomycin against vancomycin-resistant Enterococcus faecium in an in vitro pharmacokinetic model. Eur. J. Clin. Microbiol. Infect. Dis. 10:1062-1065.
5. Chow, J. W., S. M. Donabedian, and M. J. Zervos. 1997. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia. Clin. Infect. Dis. 24:90-91.
6. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37:2311-2317.
7. Dutka-Malen, S., S. Evers, and P. Courvalin. 1995. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J. Clin. Microbiol. 33:24-27.
8. Dutka-Malen, S., C. Molinas, M. Arthur, and P. Courvalin. 1992. Sequence of the vanC gene of Enterococcus gallinarum BM4174 encoding a D-alanine: D-alanine ligase-related protein necessary for vancomycin resistance. Gene 112:53-58.
9. el-Mady, A., and J. E. Mortensen. 1991. The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant Enterococcus faecium. Diagn. Microbiol. Infect. Dis. 14:141-145.
10. Evers, S., P. E. Reynolds, and P. Courvalin. 1994. Sequence of the vanB and ddl genes encoding D-alanine:D-lactate and D-alanine:D-alanine ligases in vancomycin-resistant Enterococcus faecalis V583. Gene 140:97-102.
11. Fuchs, P. C., A. L. Barry, and S. D. Brown. 2001. Evaluation of daptomycin susceptibility testing by E test and the effect of different batches of media. J. Antimicrob. Chemother. 48:557-561.
12. Gold, H. S. 2001. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin. Infect. Dis. 33:210-219.
13. Goldstein, E. J. C., D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell, and H. T. Fernandez. 2003. In vitro activities of daptomycin, vancomycin, quinupristin-dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates. Antimicrob. Agents Chemother. 47:337-341.
14. Jorgensen, J. H., L. A. Maher, and J. S. Redding. 1987. In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria. Eur. J. Clin. Microbiol. 6:91-96.
15. Lakey, J. H., and M. Ptak. 1988. Fluorescence indicates a calcium-dependent interaction between the lipopeptide antibiotic LY 146032 and phospholipid membranes. Biochemistry 27:4639-4645.
16. Mobarakai, N., J. M. Quale, and D. Landman. 1994. Bactericidal activities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. 38:385-387.
17. Murray, B. E. 2000. Vancomycin-resistant enterococcal infections. N. Engl. J. Med. 342:710-721.
18. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. NCCLS, Wayne, Pa.
19. NCCLS. 2003. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8. NCCLS, Wayne, Pa.
20. NCCLS. 2003. Performance standards for antimicrobial susceptibility testing. Supplement M100-S13. NCCLS, Wayne, Pa.
21. Petersen, P. J., P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum, and S. J. Projan. 2002. In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens. Antimicrob. Agents Chemother. 46:2595-2601.
22. Rice, L. B. 2001. Emergence of vancomycin-resistant enterococci. Emerg. Infect. Dis. 7:183-187.
23. Rybak, M. J., E. Hershberger, T. Moldovan, and R. G. Grucz. 2000. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob. Agents Chemother. 44:1062-1066.
24. Snydman, D. R., N. V. Jacobus, L. A. McDermott, J. R. Lonks, and J. M. Boyce. 2000. Comparative in vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens. Antimicrob. Agents Chemother. 44:3447-3450.